File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis

TitlePredicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis
Authors
KeywordsRelapse prevention
Maintenance
First-episode schizophrenia
Double blind
Randomized controlled trial
Issue Date2013
Citation
Schizophrenia Research, 2013, v. 150 n. 1, p. 297-302 How to Cite?
AbstractObjective: Relapse is common among patients with psychotic disorders. Identification of relapse predictors is important for decision regarding maintenance medication. Naturalistic studies often identify medication non-adherence as a dominant predictor. There are relatively few studies for predictors where adherence is already known. It is this situation i.e., discontinuation of medication that predictors will be most useful. We identify predictors for relapse in situations of (i) discontinuation and (ii) continuation of maintenance medication. Method: Analysis of relapse predictors is based on a randomized controlled study (n= 178) comparing relapse rates between patients who discontinued or continued medication for at least 1. year following first-episode psychosis. Demographic, clinical and neurocognitive variables were assessed at baseline as predictors of relapse within 1. year. Results: Risk of relapse was 79% in the discontinuation group and 41% in the maintenance group. Predictors in the discontinuation group were diagnosis of schizophrenia, poorer semantic fluency performance, and higher blink rate. Predictors in the continuation group were disinhibition soft signs and more general psychopathology symptoms. Conclusion: Different predictors of relapse were identified for first episode psychosis patients who discontinued and continued maintenance medication. Neurocognitive dysfunctions are important predictors for both groups. While signs of frontal dysfunction and dopamine hyperactivity predict relapse in the discontinuation group, sign of cognitive disinhibition predicts relapse in the continuation group. © 2013 Elsevier B.V.
Persistent Identifierhttp://hdl.handle.net/10722/192734
ISSN
2023 Impact Factor: 3.6
2023 SCImago Journal Rankings: 1.374
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHui, CLMen_US
dc.contributor.authorWong, GHYen_US
dc.contributor.authorTang, YMJen_US
dc.contributor.authorChang, WCen_US
dc.contributor.authorChan, SKWen_US
dc.contributor.authorLee, EHMen_US
dc.contributor.authorLam, MMLen_US
dc.contributor.authorChiu, CPYen_US
dc.contributor.authorLaw, CWen_US
dc.contributor.authorChung, DWSen_US
dc.contributor.authorTso, Sen_US
dc.contributor.authorPang, EPFen_US
dc.contributor.authorChan, KTen_US
dc.contributor.authorWong, YCen_US
dc.contributor.authorMo, FYMen_US
dc.contributor.authorChan, KPMen_US
dc.contributor.authorHung, SFen_US
dc.contributor.authorHoner, WGen_US
dc.contributor.authorChen, EYHen_US
dc.date.accessioned2013-11-20T05:00:04Z-
dc.date.available2013-11-20T05:00:04Z-
dc.date.issued2013en_US
dc.identifier.citationSchizophrenia Research, 2013, v. 150 n. 1, p. 297-302en_US
dc.identifier.issn0920-9964en_US
dc.identifier.urihttp://hdl.handle.net/10722/192734-
dc.description.abstractObjective: Relapse is common among patients with psychotic disorders. Identification of relapse predictors is important for decision regarding maintenance medication. Naturalistic studies often identify medication non-adherence as a dominant predictor. There are relatively few studies for predictors where adherence is already known. It is this situation i.e., discontinuation of medication that predictors will be most useful. We identify predictors for relapse in situations of (i) discontinuation and (ii) continuation of maintenance medication. Method: Analysis of relapse predictors is based on a randomized controlled study (n= 178) comparing relapse rates between patients who discontinued or continued medication for at least 1. year following first-episode psychosis. Demographic, clinical and neurocognitive variables were assessed at baseline as predictors of relapse within 1. year. Results: Risk of relapse was 79% in the discontinuation group and 41% in the maintenance group. Predictors in the discontinuation group were diagnosis of schizophrenia, poorer semantic fluency performance, and higher blink rate. Predictors in the continuation group were disinhibition soft signs and more general psychopathology symptoms. Conclusion: Different predictors of relapse were identified for first episode psychosis patients who discontinued and continued maintenance medication. Neurocognitive dysfunctions are important predictors for both groups. While signs of frontal dysfunction and dopamine hyperactivity predict relapse in the discontinuation group, sign of cognitive disinhibition predicts relapse in the continuation group. © 2013 Elsevier B.V.en_US
dc.languageengen_US
dc.relation.ispartofSchizophrenia Researchen_US
dc.subjectRelapse prevention-
dc.subjectMaintenance-
dc.subjectFirst-episode schizophrenia-
dc.subjectDouble blind-
dc.subjectRandomized controlled trial-
dc.titlePredicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosisen_US
dc.typeArticleen_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.schres.2013.08.010en_US
dc.identifier.pmid23993865-
dc.identifier.scopuseid_2-s2.0-84884142945en_US
dc.identifier.hkuros227761-
dc.identifier.volume150en_US
dc.identifier.issue1en_US
dc.identifier.spage297en_US
dc.identifier.epage302en_US
dc.identifier.isiWOS:000324294700050-
dc.identifier.issnl0920-9964-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats